<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Pediatr Pharmacol Ther</journal-id><journal-id journal-id-type="iso-abbrev">J Pediatr Pharmacol Ther</journal-id><journal-id journal-id-type="pmc-domain-id">1334</journal-id><journal-id journal-id-type="pmc-domain">jppt</journal-id><journal-id journal-id-type="publisher-id">jppt</journal-id><journal-title-group><journal-title>The Journal of Pediatric Pharmacology and Therapeutics : JPPT</journal-title></journal-title-group><issn pub-type="ppub">1551-6776</issn><issn pub-type="epub">2331-348X</issn><publisher><publisher-name>Pediatric Pharmacology Advocacy Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10249977</article-id><article-id pub-id-type="pmcid-ver">PMC10249977.1</article-id><article-id pub-id-type="pmcaid">10249977</article-id><article-id pub-id-type="pmcaiid">10249977</article-id><article-id pub-id-type="pmid">37303765</article-id><article-id pub-id-type="doi">10.5863/1551-6776-28.3.222</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Comparison of Antiemetics in the Management of Pediatric Cannabinoid Hyperemesis Syndrome</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Geraci</surname><given-names initials="E">Emily</given-names></name><degrees>PharmD</degrees><xref rid="aff1" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cake</surname><given-names initials="C">Carrie</given-names></name><degrees>RPh</degrees><xref rid="aff2" ref-type="aff"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mulieri</surname><given-names initials="KM">Kevin M.</given-names></name><degrees>PharmD</degrees><xref rid="aff2" ref-type="aff"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Fenn</surname><given-names initials="NE">Norman E.</given-names><suffix>III</suffix></name><degrees>PharmD</degrees><xref rid="aff3" ref-type="aff"/><xref rid="aff4" ref-type="aff"/></contrib></contrib-group><aff id="aff1">Department of Pharmacy, University of Rochester Medical Center&#8211;Golisano Children's Hospital, Rochester, NY (EG)</aff><aff id="aff2">Department of Pharmacy, Penn State Children's Hospital, Hershey, PA (CC, KMM)</aff><aff id="aff3">Department of Pharmacy Practice, Manchester University College of Pharmacy and Natural Sciences, Fort Wayne, IN (NEF)</aff><aff id="aff4">Department of Pharmacy, Parkview Regional Medical Center, Fort Wayne, IN (NEF)</aff><author-notes><corresp id="cor1"><bold>Correspondence.</bold> Norman E. Fenn III, PharmD; <email>nefenn@manchester.edu</email></corresp><fn><p>At the time of writing, EG and NEF were affiliated with Penn State Children's Hospital.</p></fn><fn fn-type="COI-statement"><p><bold>Disclosures.</bold> The authors declare no conflicts or financial interest in any product or service mentioned in the manuscript, including grants, medications, employment, gifts, and honoraria. The authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</p></fn></author-notes><pub-date pub-type="epub"><day>2</day><month>6</month><year>2023</year></pub-date><pub-date pub-type="ppub"><year iso-8601-date="2023">2023</year></pub-date><volume>28</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">437759</issue-id><fpage>222</fpage><lpage>227</lpage><history><date date-type="received"><day>31</day><month>5</month><year>2022</year></date><date date-type="accepted"><day>16</day><month>8</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>09</day><month>06</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-06-23 18:25:10.640"><day>23</day><month>06</month><year>2023</year></date></event></pub-history><permissions><copyright-statement><bold>Copyright.</bold> Pediatric Pharmacy Association. All rights reserved. For permissions, email: <email>membership@pediatricpharmacy.org</email> 2023</copyright-statement><copyright-year>2023</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="i2331-348X-28-3-222.pdf"/><abstract><sec><title>OBJECTIVE</title><p>As a result of recent legislative changes allowing for increased access to marijuana products, there have been increasing rates of cannabis abuse among adolescents and subsequent diagnoses of cannabinoid hyperemesis syndrome (CHS). Most available literature on this syndrome exists within the adult population and describes benzodiazepines, haloperidol, and topical capsaicin as potentially efficacious in the management of CHS. The objectives of this study were to identify antiemetics and compare their efficacy and safety in the management of pediatric CHS.</p></sec><sec><title>METHODS</title><p>A retrospective review of Penn State Children's Hospital electronic health record was performed to identify patients 18 years or younger who had an emergency department or inpatient encounter, a cannabis hyperemesis&#8211;related diagnosis code, and met diagnostic criteria for CHS. Antiemetic efficacy was determined using subjective patient perception of nausea and objective documentation of vomiting. Benzodiazepines, haloperidol, and topical capsaicin were classified as nontraditional antiemetics, whereas all other antiemetics were classified as traditional.</p></sec><sec><title>RESULTS</title><p>Nontraditional antiemetic medications appeared to be more effective in resolving patient symptoms compared with traditional antiemetics. Analysis of all ordered antiemetics demonstrated a gap in partial or full symptom resolution between nontraditional and traditional agents. Reported adverse effects were minimal.</p></sec><sec><title>CONCLUSIONS</title><p>Cannabinoid hyperemesis syndrome is an underrecognized and underdiagnosed condition characterized by cyclic vomiting related to chronic cannabis use. Abstinence from cannabis remains the most effective approach to mitigating morbidity associated with CHS. Medications such as lorazepam or droperidol may have benefit in managing toxidrome symptoms. Traditional antiemetic prescribing remains a key barrier to effective management of pediatric CHS.</p></sec></abstract><kwd-group><kwd>cannabinoid hyperemesis syndrome</kwd><kwd>cannabis</kwd><kwd>emesis</kwd><kwd>hyperemesis</kwd><kwd>marijuana</kwd><kwd>pediatric</kwd></kwd-group><counts><page-count count="6"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>